Search results
DOAC-Remove™50
Removes DOACs and argatroban from citrated plasmas thereby reducing interference when the plasma is tested in laboratory coagulation assays such as aPTT, TT, single factors, lupus AC, and APC-R.
DOAC-Remove™250
Removes DOACs and argatroban from citrated plasmas thereby reducing interference when the plasma is tested in laboratory coagulation assays such as aPTT, TT, single factors, lupus AC, and APC-R.
DP-Filter®
DP-Filter®is effective in filtering direct oral anticoagulants (DOACs), which interfere in various coagulometric coagulation tests, from citrated plasma providing anticoagulant-free plasma that can be used for testing. For research use only.
ELISA Dilution buffer, with albumin, pH 7.50
For immuno-enzymatic assays.
Epinephrine
Investigation of congenital (e.g., Glanzmann’s thrombasthenia, gray platelet syndrome) or acquired thrombopathy (e.g. myelodisplasic or myeloproliferative syndrome, Waldenström’s disease, multiple myeloma). Follow-up of patients treated with antiplatelet drugs such as aspirin, thienopyridines, abciximab and other NSAIDsand GPIIb/IIIa inhibitors.
Factor II (Fragment 1), Human
Factor II (Fragment 2), Human
Factor II (Prothrombin) Deficient Plasma
Measurement of factor II (FII / prothrombin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human prothrombin deficient plasma is required.
Factor II (Prothrombin) Deficient Plasma
Measurement of Factor II (FII / prothrombin) activity in human citrated plasma using a clotting method, triggered with calcium thromboplastin. For any in vitro protocol or research study where a source of human prothrombin deficient plasma is required.
Factor II (Prothrombin), anti-human, mouse, IgG